This is a working overview of GRF(1-29), written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual descriptor; not a measure of purity |
| Solubility class | Freely soluble in water | Aqueous dissolution may require gentle mixing |
| Typical storage (powder) | −20 °C or below, desiccated | Protect from light and ambient moisture |
| Typical storage (solution) | 2–8 °C, short term | Freeze aliquots where longer holding is needed |
| Purity assessment | Reversed-phase HPLC, area percent | Values depend on column, gradient, and detection wavelength |
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
=== Distillation === When distilled, cider turns into fruit brandy. Calvados is the apple brandy traditional to the France Normandy region, while Applejack is the traditional North American cider distillate.
However, subsequent clinical studies found that this was not also the case for humans, indicating species differences; bicalutamide crosses into the human brain and, in accordance, produces effects and side effects consistent with central antiandrogenic action. In any case, there is indication that bicalutamide might have at least some peripheral selectivity in humans. Bicalutamide is highly plasma protein bound (96.1% for racemic bicalutamide, 99.6% for (R)-bicalutamide) and is bound mainly to albumin, with negligible binding to SHBG and corticosteroid-binding globulin. Bicalutamide is metabolized in the liver. (R)-Bicalutamide is metabolized slowly and almost exclusively via hydroxylation by CYP3A4 into (R)-hydroxybicalutamide. This metabolite is then glucuronidated by UGT1A9. In contrast to (R)-bicalutamide, (S)-bicalutamide is metabolized rapidly and mainly by glucuronidation (without hydroxylation). None of the metabolites of bicalutamide are known to be active and levels of the metabolites are low in plasma, where unchanged biclautamide predominates. Due to the stereoselective metabolism of bicalutamide, (R)-bicalutamide has a far longer terminal half-life than (S)-bicalutamide and its levels are about 10- to 20-fold higher in comparison following a single dose and 100-fold higher at steady-state. (R)-Bicalutamide has a relatively long elimination half-life of 5.8 days with a single dose and 7 to 10 days following repeated administration.
=== 24 December === The RSF captured the towns of Abu Qamra and Ambara, while the SAF and JDF withdrew towards Tine and Karnoi along the Chadian border which are the last areas in Darfur under SAF control. The RSF also claimed to have recaptured Alouba, two days after it was captured by the SAF.
=== 19th century === Building on earlier studies, further glimpses of developmental bioelectricity occurred with the discovery of wound-related electric currents and fields in the 1840s, when the electrophysiologist Emil du Bois-Reymond reported macroscopic level electrical activities in frog, fish and human bodies. He recorded minute electric currents in live tissues and organisms with a then state-of-the-art galvanometer made of insulated copper wire coils. He unveiled the fast-changing electricity associated with muscle contraction and nerve excitation – the action potentials. Du Bois-Reymond also reported in detail less fluctuating electricity at wounds – injury current and potential – he made to himself.
Sources: en.wikipedia.org
To ensure highly anisotropic, yet predictable solidification behavior within the SSZ, dynamic freezing patterns are preferred. Using dynamic freezing, the velocity of the solidification front, and, therefore, the ice crystal size, can be controlled with a changing temperature gradient. The increasing thermal gradient counters the effect of the growing thermal buffer imposed by the growing ice front. It has been shown that a linearly decreasing temperature on one side of a freeze-cast will result in near-constant solidification velocity, yielding ice crystals with an almost constant thickness along the SSZ of an entire sample. However, as pointed out by Waschkies et al. even with constant solidification velocity, the thickness of the ice crystals does increase slightly over the course of freezing. In contrast to that, Flauder et al. demonstrated that an exponential change of the temperature at the cooling plate leads to a constant ice crystal thickness within the complete SSZ, which was attributed to a measurably constant ice-front velocity in a distinct study. This approach enables a prediction of the ice-front velocity from the thermal parameters of the suspension. Consequently, if the exact relationship between the pore diameter and ice-front velocity is known, an exact control over the pore diameter can be achieved.
1934 The first widely known scientific publication on the impact of dietary restriction on life expectancy, authored by Clive McCay. McCay's group carried out intensive research in this direction in 1930–43, soon other scientists began to do related research. The effect of increasing life expectancy by starvation is usually observed in rats and mice, whose development until puberty is very labile (growth retardation and puberty, decreased metabolism and body temperature). In larger animals, such as rabbits, dogs and monkeys, the effect is less pronounced. The impact of fasting on human life expectancy still remains a question where not everything is clear and is unambiguous. 1936 The first European (and Western) journal about aging and longevity. It was published in Kishinev by Dimu Kotsovsky. During the first year of existence it was called Monatsberichte, then got the name German: Altersprobleme: Zeitschrift für Internationale Altersforschung und Altersbekämpfung = "Problems of Aging: Journal for the International Study and Combat of Aging". The journal published materials mostly in the German language, less in French and English. 1937 A Ukrainian Soviet pathophysiologist Alexander Bogomolets created antireticular cytotoxic serum in the hope to extend life of people to 150 years. Although the drug did not achieve its main goal, it has become widely used for the treatment of a number of diseases, especially infectious diseases and fractures. The serum of Bogomolets was actively used in Soviet hospitals during WWII.
=== Tony Day === Tony Day (Stephen Campbell Moore) is Tender’s EMEA CFO, based in Accra and described by Jonah as Whitney’s “lieutenant.” Sweetpea grows suspicious after seeing his name repeatedly in internal emails and learning he was promoted to CFO despite prior career failures, overseeing Tender’s acquisition of an African third-party payment processor. She travels to Accra with Kwabena to investigate. Day is initially evasive but later reveals that recently deceased FinDigest reporter Jim Dycker had discussed potential whistleblowing “pathways” with him. After Sweetpea uncovers evidence that Tender falsified profits in Africa by recycling fake revenue, Day agrees to be interviewed and travels to London to meet her and FinDigest editor Edward Burgess. Whitney intervenes and convinces him to stay loyal, having been warned that the Russian government (for whom Tender is a front) will assassinate Day if he speaks out; Day then appears on a live CNN debate to defend Tender’s African operations, reneging on his agreement with Sweetpea and Burgess. Day is ultimately arrested after Tender's downfall.
Sources: en.wikipedia.org
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.
There is no single agreed limit, and laboratory practice varies widely. Refrigeration slows degradation, and freezing aliquots is often described for longer holding. Any visible cloudiness or precipitate indicates the solution should be discarded.
Mass spectrometry provides the most direct confirmation through molecular mass. Reversed-phase chromatography supports purity assessment, and peptide mapping or amino acid analysis can corroborate sequence. No single method establishes both purity and identity on its own.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.